Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARMYDA-9 DAPA
2021-002813-33Phase 4Terminated
- Sponsor
- Azienda Ospedaliero-Universitaria Maggiore della Carità
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dapagliflozin in myocardial infarction (MI) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Azienda Ospedaliero-Universitaria Maggiore della Carità. Primary endpoint: Infarct size. Started Jan 2022; status: terminated.
02
Drugs
dapagliflozin
03
Conditions
myocardial infarction (MI)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2021-002813-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002813-33.